Group 1 - The company has signed a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine product [2][3] - The total technology transfer fee is set at 15 million yuan, which will be paid in installments as per the contract [6] - The contract includes provisions for intellectual property rights, ensuring that the technology and any resulting innovations will belong to the company, while the hospital retains certain academic rights [7][8] Group 2 - The technology being transferred involves the "Er Zhi Tiao Jing Optimization Formula," aimed at developing a new drug for treating conditions related to kidney deficiency [2][3] - The company is responsible for conducting all necessary research and regulatory submissions to achieve national drug registration for the new product [5] - The contract stipulates confidentiality obligations that extend for 20 years post-termination, ensuring that sensitive information remains protected [11][12] Group 3 - The contract outlines specific conditions under which either party can terminate the agreement, including failure to meet research milestones or submission deadlines [13][14] - Dispute resolution will be handled through negotiation, and if unresolved, will be taken to the competent court [17] - The contract is valid for 20 years and requires mutual consent for any amendments [20]

Core Viewpoint - The announcement indicates that the company, Buchang Pharma, is entering into a technology transfer agreement with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine aimed at treating specific health conditions [1] Group 1: Company Developments - Buchang Pharma's subsidiary, Shandong Danhong, plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital [1] - The total price for the technology transfer of the traditional Chinese medicine "Erzhi Tiaojing Optimized Formula" is set at 15 million yuan [1] - The collaboration aims to develop a Class 1 new drug for treating conditions related to kidney deficiency and ovarian reserve function decline [1] Group 2: Research and Development - The parties will conduct research on the new traditional Chinese medicine and aim to obtain a national drug registration certificate [1] - Successful development will lead to industrial-scale production of the new drug [1]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]